We could not find any results for:
Make sure your spelling is correct or try broadening your search.
ABVC BioPharma licenses promising medical research conducted in the Asia-Pacific region and enlists top-ranked principal investigators in the United States to conduct Phase II clinical trials. We specialize in botanically based solutions that deliver high efficacy with low toxicity for improved heal... ABVC BioPharma licenses promising medical research conducted in the Asia-Pacific region and enlists top-ranked principal investigators in the United States to conduct Phase II clinical trials. We specialize in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes that represent enormous commercial potential. Show more
FREMONT, CA, March 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
FREMONT, CA, March 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions...
FREMONT, CA, March 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions...
FREMONT, CA, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a biotechnology company specializing in botanically based solutions that...
true Amendment no. 1 to Form 8-k 0001173313 0001173313 2024-01-16 2024-01-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares...
true Amendment no. 1 to Form 8-k 0001173313 0001173313 2023-11-20 2023-11-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares...
FREMONT, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
As filed with the Securities and Exchange Commission on February 16, 2024 Registration No. 333-276500 Registration No. 333-271416 SECURITIES AND EXCHANGE COMMISSION Washington...
FREMONT, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.2 | 18.5185185185 | 1.08 | 1.45 | 1.03 | 5820912 | 1.27415698 | CS |
4 | 0.08 | 6.66666666667 | 1.2 | 1.45 | 1.03 | 1524557 | 1.27015146 | CS |
12 | -0.57 | -30.8108108108 | 1.85 | 1.85 | 1.03 | 846034 | 1.31907477 | CS |
26 | 0.25 | 24.2718446602 | 1.03 | 3.35 | 0.6739 | 2412773 | 1.53712465 | CS |
52 | -4.72 | -78.6666666667 | 6 | 9.6 | 0.6739 | 1434757 | 2.0133156 | CS |
156 | -31.92 | -96.1445783133 | 33.2 | 116.883 | 0.6739 | 1010338 | 18.58117356 | CS |
260 | -31.92 | -96.1445783133 | 33.2 | 116.883 | 0.6739 | 1010338 | 18.58117356 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions